WHO enrolled first patients in a clinical trial testing remdesivir and MBP-134 against Bundibugyo virus, announced around July 2, 2026.
WHY THIS MATTERS · This matters because an Ebola flare-up that jumps a porous DRC border into a city or refugee corridor can overwhelm fragile health systems fast, and the only real brakes are limited vaccine stockpiles and rapid-response teams that take days to deploy.
Part of the monitored dynamic Ebola Outbreak Tracking · VUCA INDEX 56/100
"Last Thursday, the World Health Organization announced that the first patients were enrolled in a clinical trial designed to test two drugs against Bundibugyo."
"The trial of two potential treatments for Bundibugyo began in the DRC on July 2. The trial is evaluating the effectiveness of the monoclonal antibody MBP134 and the antiviral drug remdesivir"
Extracted by pipeline v0.5 (claude-opus-4-8) from interlochenpublicradio.org · approved by christopher@vucanews.com JUL 8.
Extracted JUL 7; approved JUL 8 at 0.58. Corroborated by manilatimes.net JUL 10; confidence 0.58 → 0.70. Corroborated by turnto23.com JUL 14; confidence 0.70 → 0.78.
- A humanitarian doctor tested positive for Ebola in France, the first case on French territory, after flying from DRC on 23 June 2026.
- The French Ebola patient recovered after two negative PCR tests and was discharged, French Health Minister Stéphanie Rist said.
- Five other passengers on the doctor's Air France flight were identified as possible contacts and placed in isolation.
- An Ebola case was recently confirmed in Kisangani, a major DRC city 600 km from the outbreak epicentre.
- The US placed itself on alert over the DRC Ebola outbreak, implementing stepped-up surveillance and entry restrictions on airline travelers.